Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
$18.02
-$0.83(-1.65%)
At close: 4:00 PM EST
$18.02
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)1.26M
Market Cap
$1.28B
Enterprise Value$1.02B
Total Cash (Recent Filing)$393.97M
Total Debt (Recent Filing)$75.71M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
May 07, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding70,847,404
10 Day Avg. Volume1,359,585
30 Day Avg. Volume1,255,288
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-454.81
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$25.92Price Target Upside43.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Imaging And Biomarker EvidenceMagnetic resonance imaging and biomarker results demonstrated reduced inflammation and bone remodeling in axial spondyloarthritis patients, suggesting potential disease-modifying effects that could differentiate the therapy.
Financial RunwayA substantial cash balance combined with access to non-dilutive financing provides a development runway to reach key milestones and pursue additional indications without immediate shareholder dilution.
Regulatory StrategyFDA indicated that mid-stage trial data can be included to support a biologics license application, which may shorten the pathway to approval for the hidradenitis suppurativa program.
Bears Say
Limited Confirmatory DataEfficacy evidence in axial spondyloarthritis is largely based on a small, open-label study, limiting confidence until larger, controlled trials replicate the findings.
Phase III Trial FailureOne Phase III study narrowly missed its primary endpoint due to an increased placebo response, creating uncertainty about the lead program’s efficacy and its ability to meet regulatory standards.
Regulatory Review RiskRegulators are likely to review the full clinical dataset, including a non-confirmatory trial, increasing the risk that approval decisions or labeling could be constrained by inconsistent results.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $1.28B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Feb 22, 2026. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$0.964 by $0.034.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.91.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 70,847,404 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.93 in its last earnings report, beating expectations of -$0.964. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.92 (43.84% Upside)
$25.92 (43.84% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 12.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.93%
12-Months-Change
Fundamentals
Return on Equity
-60.51%
Trailing 12-Months
Asset Growth
-11.19%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$25.92
▲(43.84% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
Ownership Overview
36.85% Insiders
1.92% Mutual Funds
10.80% Other Institutional Investors
49.80% Public Companies and Individual Investors